FIREBRICK PHARMA LIMITED — Investor Relations & Filings

Firebrick Pharma Limited is a pharmaceutical company focused on developing and commercializing innovative therapies for respiratory viral infections. The company's primary asset is Nasodine® Nasal Spray, a broad-spectrum antiseptic formulation containing povidone-iodine (PVP-I). Nasodine is designed to target the nasal passages, the primary site where respiratory viruses, including those causing the common cold, replicate. By utilizing the established antimicrobial properties of PVP-I, the product aims to reduce viral load and alleviate symptoms at the source of infection. Firebrick Pharma's research and development efforts center on clinical validation and regulatory pathways to establish Nasodine as a first-in-class treatment for viral upper respiratory tract infections. The company focuses on addressing unmet needs in the management of the common cold through evidence-based antiseptic interventions.